Delving into the Latest Updates on Cholera vaccine live attenuated(Institute For International Vaccine Development Inc) with Synapse

Overview

Basic Info

Drug Type

Live attenuated vaccine, Prophylactic vaccine

Synonyms

Cholera vaccine live attenuated, CholeraGarde, Live attenuated oral cholera vaccine

+ [1]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication

Cholera

Inactive Indication

DiarrheaMeasles

Originator Organization

Institute For International Vaccine Development Inc

Active Organization

Celldex Therapeutics, Inc.Institute For International Vaccine Development IncVaccine Technologies, Inc.

Inactive Organization

AVANT Immunotherapeutics, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

ABSTRACTVaccination is a well-established means for prevention and spread of disease in people traveling abroad. Although vaccines to diseases such as cholera are recommended by world health agencies, they are seldom required even when traveling to endemic regions. Consequences of noncompliance can affect traveler’s health and spread diseases to new regions, as occurred in Haiti in 2010 when United Nations peacekeepers from Nepal, where a cholera outbreak was underway, introduced the disease to the region. Steps to increase vaccine recommendation compliance should therefore be an integral part of vaccine development. PXVX0200 contains Center for Vaccine Development 103-HgR live, attenuated recombinant Vibrio cholerae vaccine strain, and is indicated for single-dose immunization against the bacteria that causes cholera. It is supplied as one buffer and one active component packet to be mixed into water and ingested. Administration instructions are designed to be “user friendly” with flexibility for self-administration, thus promoting compliance. Studies to support self-administration were conducted to cover stability of the vaccine outside of normal storage conditions, potency in case of misadministration, and disposal procedures to minimize environmental impact. The principal findings showed that the stability of vaccine was maintained under conditions allowing for transport times and temperature conditions as well as when misadministration errors were made. Finally, the vaccine was effectively neutralized with hot water and soap to prevent bacterial environmental contamination in the event of an accidental spill. The conclusion is that PXVX0200 oral vaccine is stable, easy to formulate and dispose of, and is amenable to self-administration.

19 Nov 2020·Journal of BacteriologyQ3 · BIOLOGY

Transient Intestinal Colonization by a Live-Attenuated Oral Cholera Vaccine Induces Protective Immune Responses in Streptomycin-Treated Mice

Q3 · BIOLOGY

Article

Author: Waldor, Matthew K. ; Fakoya, Bolutife ; Sit, Brandon

Oral cholera vaccines (OCVs) are being deployed to combat cholera, but current killed OCVs require multiple doses and show little efficacy in young children. Live OCVs have the potential to overcome these limitations, but small-animal models for testing OCVs have shortcomings. We used an antibiotic treatment protocol for conventional adult mice to study the effects of short-term colonization by a single dose of HaitiV, a live-OCV candidate. Vaccinated mice developed vibriocidal antibodies against V. cholerae and delivered pups that were resistant to cholera, whereas mice vaccinated with inactivated HaitiV did not. These findings demonstrate HaitiV’s immunogenicity and suggest that this antibiotic treatment protocol will be useful for evaluating the efficacy of live OCVs.

02 Jan 2020·Human Vaccines & ImmunotherapeuticsQ3 · MEDICINE

An overview of Vaxchora^TM, a live attenuated oral cholera vaccine

Q3 · MEDICINE

Article

Author: Kim, Jerome H. ; Saluja, Tarun ; Mogasale, Vijayalaxmi V. ; Excler, Jean-Louis ; Mogasale, Vittal

Cholera remains a public health threat among the least privileged populations and regions affected by conflicts and natural disasters. Together with Water, Sanitation and Hygiene practices, use of oral cholera vaccines (OCVs) is a key tool to prevent cholera. Bivalent whole-cell killed OCVs have been extensively used worldwide and found effective in protecting populations against cholera in endemic and outbreak settings. No cholera vaccine had been available for United States (US) travelers at risk for decades until 2016 when CVD 103-HgR (Vaxchora™), an oral live attenuated vaccine, was licensed by the US FDA. A single dose of Vaxchora™ protected US volunteers against experimental challenge 10 days and 3 months after vaccination. However, use of Vaxchora™ poses several challenges in resource poor settings as it requires reconstitution, is age-restricted to 18 to 64 years, has no data in populations endemic for cholera, and faces challenges related to cold chain and cost.

100 Deals associated with Cholera vaccine live attenuated(Institute For International Vaccine Development Inc)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cholera	Phase 2	-	Vaccine Technologies, Inc.	-
Cholera	Phase 2	-	Celldex Therapeutics, Inc.	-
Cholera	Phase 2	-	Institute For International Vaccine Development Inc	-
Diarrhea	Phase 1	IN	Vaccine Technologies, Inc.	01 Nov 2008
Diarrhea	Phase 1	BD	Vaccine Technologies, Inc.	01 Nov 2008
Diarrhea	Phase 1	IN	AVANT Immunotherapeutics, Inc.	01 Nov 2008
Diarrhea	Phase 1	BD	AVANT Immunotherapeutics, Inc.	01 Nov 2008
Diarrhea	Discovery	BD	Vaccine Technologies, Inc.	01 Nov 2008
Diarrhea	Discovery	IN	Vaccine Technologies, Inc.	01 Nov 2008
Diarrhea	Discovery	IN	AVANT Immunotherapeutics, Inc.	01 Nov 2008